Pharmaceutical Industry discussion, review, analysis, news and information.

Clinical data of a completed Phase 2 follow-up study of Flurizan™ in patients with mild Alzheimer's disease indicate that Flurizan may be capable, not only of slowing the decline of Alzheimer's disease, but of halting the disease in its tracks.

At 24 months, study participants in the Phase 2 trial with mild Alzheimer's disease taking 800 mg twice daily Flurizan experienced a 67% improvement in their level of cognitive decline compared with placebo, as measured by the Mini Mental State Exam (MMSE) score. This difference was highly significant statistically (p=0.001).

The findings were reported by Myriad Genetics, Inc. (Nasdaq: MYGN) recently at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), held March 1-4, 2007 in New Orleans.

Flurizan™ -the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs) - lowered levels of Abeta42 in cellular assays and animal models.

Abeta42, the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease (AD), is thought to be the key initiator of the disease.

Find more details from the full report.